S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
bluebird bio stock is ripe for a 400% institutional short squeeze
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
3 lithium stocks to ride a multi-year cycle
Goldman upgraded Nvidia stock, one metric says it could go higher
Critical asset just had biggest fall on record (Ad)
Salesforce stock got a boost. Is it growing off the Nvidia boom?
Autozone stock price is still in the rally zone
Critical asset just had biggest fall on record (Ad)
Closing prices for crude oil, gold and other commodities
New highs are coming for Lowe’s stock despite mixed results
S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
bluebird bio stock is ripe for a 400% institutional short squeeze
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
3 lithium stocks to ride a multi-year cycle
Goldman upgraded Nvidia stock, one metric says it could go higher
Critical asset just had biggest fall on record (Ad)
Salesforce stock got a boost. Is it growing off the Nvidia boom?
Autozone stock price is still in the rally zone
Critical asset just had biggest fall on record (Ad)
Closing prices for crude oil, gold and other commodities
New highs are coming for Lowe’s stock despite mixed results
S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
bluebird bio stock is ripe for a 400% institutional short squeeze
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
3 lithium stocks to ride a multi-year cycle
Goldman upgraded Nvidia stock, one metric says it could go higher
Critical asset just had biggest fall on record (Ad)
Salesforce stock got a boost. Is it growing off the Nvidia boom?
Autozone stock price is still in the rally zone
Critical asset just had biggest fall on record (Ad)
Closing prices for crude oil, gold and other commodities
New highs are coming for Lowe’s stock despite mixed results
S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
bluebird bio stock is ripe for a 400% institutional short squeeze
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
3 lithium stocks to ride a multi-year cycle
Goldman upgraded Nvidia stock, one metric says it could go higher
Critical asset just had biggest fall on record (Ad)
Salesforce stock got a boost. Is it growing off the Nvidia boom?
Autozone stock price is still in the rally zone
Critical asset just had biggest fall on record (Ad)
Closing prices for crude oil, gold and other commodities
New highs are coming for Lowe’s stock despite mixed results
NASDAQ:DCTH

Delcath Systems (DCTH) Stock Price, News & Analysis

$4.23
+0.02 (+0.48%)
(As of 02/27/2024 ET)
Today's Range
$4.17
$4.28
50-Day Range
$3.52
$4.79
52-Week Range
$2.25
$7.99
Volume
101,025 shs
Average Volume
207,452 shs
Market Capitalization
$93.27 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.00

Delcath Systems MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
325.5% Upside
$18.00 Price Target
Short Interest
Healthy
3.52% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.51mentions of Delcath Systems in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$99,960 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($2.64) to ($1.90) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.84 out of 5 stars

Medical Sector

254th out of 944 stocks

Surgical & Medical Instruments Industry

32nd out of 88 stocks


DCTH stock logo

About Delcath Systems Stock (NASDAQ:DCTH)

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma. The company also provides HEPZATO as a stand-alone medical device for sale under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.

DCTH Stock Price History

DCTH Stock News Headlines

Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Delcath Systems Inc DCTH
Delcath Systems Inc. Q3 Loss Increases
Delcath Systems Q3 2023 Earnings Preview
Delcath Systems to Host Third Quarter 2023 Results Call
See More Headlines
Receive DCTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Delcath Systems and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/27/2023
Today
2/27/2024
Next Earnings (Estimated)
3/25/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:DCTH
Employees
52
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$18.00
High Stock Price Target
$21.00
Low Stock Price Target
$13.00
Potential Upside/Downside
+325.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-36,510,000.00
Net Margins
-2,079.17%
Pretax Margin
-2,079.17%

Debt

Sales & Book Value

Annual Sales
$2.72 million
Book Value
($0.58) per share

Miscellaneous

Free Float
17,394,000
Market Cap
$93.27 million
Optionable
Optionable
Beta
0.53
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for March 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report














DCTH Stock Analysis - Frequently Asked Questions

Should I buy or sell Delcath Systems stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Delcath Systems in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" DCTH shares.
View DCTH analyst ratings
or view top-rated stocks.

What is Delcath Systems' stock price target for 2024?

4 analysts have issued twelve-month price objectives for Delcath Systems' stock. Their DCTH share price targets range from $13.00 to $21.00. On average, they predict the company's stock price to reach $18.00 in the next year. This suggests a possible upside of 325.5% from the stock's current price.
View analysts price targets for DCTH
or view top-rated stocks among Wall Street analysts.

How have DCTH shares performed in 2024?

Delcath Systems' stock was trading at $4.16 at the beginning of 2024. Since then, DCTH stock has increased by 1.7% and is now trading at $4.23.
View the best growth stocks for 2024 here
.

When is Delcath Systems' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 25th 2024.
View our DCTH earnings forecast
.

How were Delcath Systems' earnings last quarter?

Delcath Systems, Inc. (NASDAQ:DCTH) released its quarterly earnings data on Monday, March, 27th. The company reported ($0.86) EPS for the quarter, missing analysts' consensus estimates of ($0.76) by $0.10. The business had revenue of $0.64 million for the quarter, compared to analyst estimates of $1.97 million. Delcath Systems had a negative trailing twelve-month return on equity of 2,571.64% and a negative net margin of 2,079.17%.

When did Delcath Systems' stock split?

Delcath Systems shares reverse split on Tuesday, October 22nd 2019. The 1-100 reverse split was announced on Friday, October 18th 2019. The number of shares owned by shareholders was adjusted after the market closes on Monday, October 21st 2019. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

Who are Delcath Systems' major shareholders?

Delcath Systems' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include AIGH Capital Management LLC (5.36%), Vivo Capital LLC (3.88%), Vanguard Group Inc. (2.37%), Worth Venture Partners LLC (1.33%), ADAR1 Capital Management LLC (1.05%) and Northern Trust Corp (0.28%). Insiders that own company stock include Ernest C Garcia II, Gerard J Michel, John Purpura, John Richard Sylvester, Rosalind Advisors, Inc, Sandra Pennell, Steven A J Salamon and Vojo Vukovic.
View institutional ownership trends
.

How do I buy shares of Delcath Systems?

Shares of DCTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:DCTH) was last updated on 2/28/2024 by MarketBeat.com Staff